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Background: The use of palliative radiotherapy (PRT) is variable in advanced cancer. Little is known about PRT
utilization by end-of-life (EOL) cancer patients in Canada. This study examined the PRT utilization rates and factors
associated with its use in a cohort of cancer patients who died in British Columbia (BC).
Methods: BC residents with invasive cancer who died between April 1, 2010 and March 31, 2011 were included in the
study. Their cancer registry and radiotherapy treatment records were extracted from the BC Cancer Agency information
systems and linked for the analysis. The PRT utilization rates by age, sex, primary cancer diagnosis, geographic region,
survival time and travel time to the cancer centre were examined. Multivariable logistic regression was used to
determine the factors that influenced the PRT utilization rates.
Results: Of the 12,300 decedents in the study 2,669 (21.7%) had received at least one course of PRT in their last year of
life. The utilization rates dropped to 5.0% and 2.2% in the last 30 and 14 days of life, respectively. PRT utilization varied
across diagnosis and was highest for lung cancer (45.7%) and lowest for colorectal cancer (8.9%). The rates also varied
by age, survival time and travel time to the nearest radiotherapy centre. There was a greater odds of receiving PRT for
those with primary lung cancer, survival time between 1.5-26 months from diagnosis or living within 2 hours from a
cancer centre. The 85+ age group was least likely to receive PRT in their last year of life.
Conclusions: This study found PRT utilization rates of EOL cancer decedents to be variable across the province of BC.
Age, diagnosis, survival time and travel time to the nearest radiotherapy centre were found to influence the odds of
PRT treatment. Further work is still needed to establish the appropriate PRT utilization rates for the EOL cancer
population.
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Palliative radiotherapy (PRT) is an established treatment
modality in the management of advanced cancer [1]. It
is also a potentially effective treatment option for cancer
patients at end of life (EOL) to enhance their quality of
life when faced with only weeks or months to live [2].
Anecdotally PRT is thought to be commonly used.
Data at the population level on the use of PRT in routine
practice is hard to find. One study estimated that approxi-
mately 50% of all RT treatments are prescribed with* Correspondence: jinhuang@uvic.ca
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unless otherwise stated.palliative intent [3], but to our knowledge no optimal PRT
utilization rates have been established for EOL cancer
patients. Several population-based studies on the PRT
utilization across major primary cancer sites by EOL cancer
patients had been performed in Ontario and Nova Scotia.
The overall rates reported in these studies were similar,
22% - 29% [4-6]. While the overall PRT rates reported were
similar across the studies, there were significant variations
for site-specific rates, e.g. lung cancer rates ranged from
40% to 58% [3,4]. In addition, many studies found the likeli-
hood of PRT decreased with increased age, lower commu-
nity median household income, and longer distance from
the cancer centre [4-6] and one study [6] found females
had lower PRT rates. Aside from these studies, we are notLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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timated optimal rates for EOL cancer patients in Canada.
Understanding PRT use by EOL cancer patients can
provide valuable information for cancer care providers and
policy makers in assessing whether these patients have ad-
equate PRTaccess to improve their quality of life.
This paper describes a retrospective cohort study on PRT
utilization rates of EOL cancer decedents in BC. Its objec-
tives were to determine: (a) the PRT utilization rates by age,
sex, primary diagnosis, geographic region, survival time and
travel time to nearest radiotherapy centre; (b) the propor-
tion of decedents who received at least one course of PRT
treatment during the last 30 and 14 days of life; and (c) the
decedent, disease and health system related factors associ-
ated with receiving PRT in the last year of life.
Methods
Study context and population
BC is the third-largest province in Canada with a popu-
lation of 4.5 million over an area of 947,800 km2 [7].
Health care in BC is delivered through one provincial
and five regional health authorities. The BC Cancer
Agency (BCCA) is part of the provincial authority called
the Provincial Health Services Authority and it offers a
province-wide, population-based cancer control pro-
gram. Currently, the BCCA has six cancer centres lo-
cated across the province to serve BC residents. The
province is divided into 16 Health Service Delivery Areas
(HSDA). Each of the six cancer centres is responsible for
a defined catchment area with a collection of these
HSDAs. Note that at the time of this study there were
only five cancer centres in operation.
The BC Cancer Registry receives, by law, notification
of all initial diagnoses of cancer in BC. The BCCA
provides cancer treatment for patients who have been
diagnosed with cancer and referred by a physician [8].
The types of treatment provided at the BCCA include
RT, chemotherapy and, in Vancouver, surgery. Approxi-
mately 60% of the patients who are registered in the BC
Cancer Registry will eventually be referred to the BCCA
for treatment [9]. Surgical treatments and some chemo-
therapy treatments are also provided in acute care
settings outside of the BCCA. RT treatment is only avail-
able through the six cancer centres [10], and all RT
treatment records are maintained centrally through the
Cancer Agency Information System (CAIS).
Data sources and study variables
Study Cohort – Patients who died between April 1, 2010
and March 31, 2011 were identified from the Cancer
Registry. Those diagnosed with invasive cancer other
than non-melanoma skin cancer were included in the
study. Those with benign or in situ tumors were ex-
cluded. This cohort was used as the denominator for thePRT utilization rates in our study. Note that due to the
lack of cause of death data for all study participants, our
study cohort consisted of all who died with invasive can-
cer in a specified time period regardless of cause. The data
fields extracted from the Cancer Registry were birthdate,
sex, date of death, histology code for primary cancer diag-
nosis, date and site of diagnosis, and HSDA residence at
time of diagnosis. The data fields extracted from CAIS
were RT course start date, treatment dose, site and intent.
This study was part of a larger EOL care surveillance net-
work project that focused on health service use in the last
year of life for identified palliative patients with advanced
illness [11]. The variables for this study are defined below.
Course of treatment – The PRT utilization was measured
by the course of treatment. For all the treatment sites with
exception of Skin and Bone, a course of treatment was
uniquely identified by RT start date, end date, and treat-
ment region. For the treatment site of Skin and Bone, every
RT record was counted as a new course of treatment re-
gardless of the RT start and end date.
PRT - A course of RT was defined as palliative if there
was a palliative intent code provided by the treating radi-
ation oncologist or if the dose of treatment was 30 Gy or
less. The dose of 30 Gy was selected as a cut point based
on the distribution of RT dose delivered for courses with a
palliative intent code in our study cohort (see Additional
file 1: Appendix A).
PRT1Y and RT1Y - The proportion of the study cohort
that had at least one course of PRT in the last year of
life (PRT1Y) was used to describe utilization of PRT.
Similarly, RT1Y was used to describe the proportion of
the study cohort that had at least one course of RT in
the last year of life.
PRT30d and PRT14d – The proportion of the study cohort
that had at least one course of PRT in the last 30 (PRT30d)
and 14 (PRT14d) days of life. Last 14 days before death was
used by Earle et al. [12] as cut-off for quality of care indica-
tors for cancer care at the end of life; last 30 days was used
by Guadagnolo et al. [13] to report on RT utilization for
elderly patients in the United States at the end of life.
Primary Diagnosis - Decedents were grouped by their pri-
mary cancer diagnosis in ICD-O-3 based on the site and
histology codes in their Registry record (see Additional
file 2: Appendix B). The primary diagnosis was assigned
based on the last known primary cancer diagnosis by the
date of diagnosis. If multiple cancer diagnoses from different
sites were found on the most recent date of cancer diagno-
sis, a predefined hierarchy was used to assign the diagnosis
based on overall cancer mortality rate: Lung > Breast >
Colorectal > Prostate > non-colorectal gastrointestinal (GI) >
Blood >Urinary > Female genital > Brain >Cancer-other.
Travel Time – The travel time from a decedent’s resi-
dence to the closest cancer centre was measured using
distance calculator provided by the British Columbia
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from the centre of the HSDA where the decedent resided
when the last primary cancer was diagnosed before he or
she died to the closest cancer centre using the postal code
of two measurement points. The travel time was grouped
into < =2 and >2 hours for each HSDA. The 2-hour cut-off
was chosen for each HSDA based on earlier work by
Tyldesley et al. [14]. In BC only 4% of the rural regions are
within a 2-hour drive of a cancer centre, whereas 46% of the
semi-rural regions and 100% of the urban regions are within
a 2-hour drive to a cancer centre [14]. The 2-hour distance
provided a balanced cut-off that reflects the geographic dif-
ferences between rural and urban residents in BC.
Survival Time - The time from the last primary cancer
diagnosis to death was categorized into three groups
of >26 months, 1.5-26 months and <1.5 months. These
survival groups had also been used in an earlier study by
Lavergne et al. [6] as a predictor of PRT utilization at
end of life.Statistical analysis
Categorical variables were used to analyze age at death
(age < 19, 19–44, 45–64, 65–74, 75–84 or ≥85 years),
primary cancer diagnosis (Blood, Brain, Breast, Colorectal,
Female Genital, Lung, Melanoma, non-colorectal GI,
Prostate, Urinary, or Other), the decedent’s residence in
one of 16 HSDAs at time of diagnosis, and survival time
from primary cancer diagnosis (<1.5, 1.5-26 or >26 months).
Binary variables were used to analyze sex, travel time to
the closest cancer centre (≤2 hours/>2 hours), receipt
of RT (yes/no) and receipt of PRT (yes/no).
Baseline characteristics were stratified by the receipt of
PRT in the last year of life. Logistic regression was used to
determine the association between the receipt of PRT and
the demographic and clinical factors. Individual factors
were modeled first to check for univariable association
with the receipt of PRT. Individual variables with a sig-
nificance level of ≤0.05 were then considered for the
multivariable model. Multivariable logistic regression
was used to identify the factors associated with the re-
ceipt of PRT in the last year of life at a significance
level of ≤0.05. Point estimates from the multivariable
model were reported as odds ratios (ORs) with the con-
fidence interval (CI) for each OR. All statistical analyses
were done with SAS statistical software package (version
9.0; SAS Institute Inc., Cary. NC).
This research was approved by the University of
Victoria Ethics Board (#12-262). A waiver from a full
ethical review of research involving human participants
was received from the University of Victoria Ethics
Board due to the fact that this research was limited to
second analyses of anonymized data, which cannot iden-
tify, or be linked to, the individuals who provided it.Results
Study cohort characteristics
An initial cohort of 13,250 decedents who died between
April 1, 2010 and March 31, 2011 were identified from the
BC Cancer Registry. The final cohort had 12,300 decedents
after excluding 945 with non-melanoma skin cancer
and 5 with data quality issues. The majority of the de-
cedents were ≥65 yrs of age. Over half (56.3%) resided
in five major geographic regions: Fraser North (10.9%),
Fraser South (13.2%), Okanagan (10.5), South Vancou-
ver Island (10.3%) and Vancouver (11.4%). The majority
of decedents (76.3%) lived less than 2 hours driving dis-
tance from the closest cancer centre. The most common
cancer diagnoses were: lung (19.6%), colorectal (12.6%),
non-colorectal gastrointestinal (GI) (11.8%), prostate
(11.7%) and breast (9.8%). Median survival time was
18.7 months. Close to 15% died within 1.5 months of their
last cancer diagnosis while 41.3% died between 1.5 and
26 months from their last cancer diagnosis. The character-
istics of the study cohort are summarized in Table 1.
PRT Utilization rates in last year of life
Of the 12,300 decedents in the study cohort, 2,959 (24.1%)
were identified as having received at least one course of RT
in their last year of life (Table 1). The majority (91.5%) of RT
treatments were palliative by our definition. The median
time to death following the first course of PRT was 102 days.
The overall proportion of decedents who received PRT in
the last year was 21.7%.
The RT1Y and PRT1Y rates varied across cancer groups
(Figure 1). PRT1Y rates were highest (45.7%) for lung,
intermediate (20-30%) for urinary, melanoma and breast,
and low (<20%) for non-colorectal GI, prostate, blood,
female genital, brain and colorectal. For most cancer
groups, the majority of decedents, when treated with RT
during their last year of life, received PRT with the excep-
tion of those with brain cancer. Just over one-third
(36.9%) of brain cancer decedents received RT in their last
year of life and less than a fifth (17.6%) received RT
deemed palliative by our definition.
On average, each decedent received 1.6 PRT courses dur-
ing their last year of life. The proportion of decedents with
at least one course of PRT in last year of life varied across
HSDAs (Figure 2). Overall, regions with a cancer centre
had higher rates than the provincial average, except for
Okanagan, which had below provincial average. PRT1Y rate
also was inversely related to travel time. Decedents who re-
sided within two hours to the closest cancer centre received
more PRT in the last year of life than those who resided far-
ther from a cancer centre (22.6% vs. 18.8%) (Table 2).
Proportion of PRT in last 30 and 14 days of life
Of the 12,300 decedents in the study, 614 (5.0%) and
268 (2.2%) received PRT in the last 30 and 14 days of
Table 1 Characteristics of study cohort, N = 12,300
Study cohort No. of decedents % Study cohort No. of decedents %
Age group Residence by Health Service Delivery Area (HSDA)
0-18 16 0.1 Central Vancouver Island 1,011 8.2
19-44 226 1.8 East Kootenay 239 1.9
45-64 2,327 18.9 Fraser East 807 6.6
65-74 2,511 20.4 Fraser North 1,346 10.9
75-84 3,613 29.4 Fraser South 1,619 13.2
85+ 3,607 29.3 Kootenay Boundary 314 2.6
Sex North Shore/Coast Garibal 820 6.7
Female 5,734 46.6 North Vancouver Island 421 3.4
Male 6,566 53.4 Northeast 124 1.0
Primary cancer diagnosis Northern Interior 371 3.0
Lung 2,406 19.6 Northwest 171 1.4
Breast 1,204 9.8 Okanagan 1,289 10.5
Colorectal 1,551 12.6 Richmond 376 3.1
Prostate 1,438 11.7 South Vancouver Island 1,270 10.3
Non-colorectal GI 1,454 11.8 Thompson Cariboo Shuswap 692 5.6
Blood 938 7.6 Vancouver 1,405 11.4
Urinary 656 5.3 Missing 25 0.2
Female Genital 623 5.1 Travel time (to closest cancer centre)
Brain 255 2.1 ≤2 hours 9,364 76.1
Melanoma 265 2.2 >2 hours 2,911 23.7
Other 1,510 12.3 Radiotherapy (RT)
Survival time from diagnosis No RT 9,341 75.9
<1.5 M 1,812 14.7 RT 2,959 24.1
1.5-26 M 5,085 41.3 Palliative RT 2,669 21.7



























Figure 1 RT1Y vs. PRT1Y rates by primary cancer. “Palliative” RT is defined as either RT intent = 'palliative' or RT dose < =30Gy.
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Figure 2 Regional PRT1Y rates. * indicates the region where a cancer center is located. Note: the horizontal line is the average provincial PRT1Y
rate and the bars show the PRT1Y rate with a 95% confidence interval for the HSDA.
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ceived PRT in the last 30 days varied across cancer
groups. The highest proportion was lung cancer at
11.3% while the lowest was colorectal cancer at 1.9%.
The remaining cancer groups ranged from melanoma at
4.9% to female genital at 2.4%. In the last 14 days the
proportions reduced by 50% or more across all groups.
Lung cancer was still the highest at 5.4% but colorectal
cancer dropped to 1.0%, while female genital was the
lowest at 0.8%. Approximately 3.1% of brain cancer
decedents received RT in the last 30 days and 1.6%
received in the last 14 days. All RT received by brain
cancer decedents in the last month of life were PRT by
our definition.
Likelihood of receiving PRT in last year of life
The univariable analysis shown in Table 2 showed that
patient-related factors such as age at death and time be-
tween diagnosis and death, disease-related factors such as
primary cancer diagnosis, and health system-related factors
such as travel time, were all significantly related to the
PRT1Y utilization rates. The age group ≥85 was found to be
significantly less likely to receive PRT during their last year
of life compared with other age groups. Decedents with pri-
mary lung cancer, survival time between 1.5-26 monthsfrom diagnosis, or residence in an HSDA area within
2 hours driving distance to a cancer centre were signifi-
cantly more likely to receive PRT in the last year of life. Sex
was not significantly related to PRT1Y rate (P = 0.28).
Statistically significant univarable factors were analyzed
using multivariable logistic regression. The variations in
PRT1Y were presented as adjusted ORs with 95% CIs after
controlling for the effects of other variables in Table 4. All
factors showed significant independent effects in associ-
ation with variation in PRT1Y. After adjusting for other
factors, age at diagnosis was negatively associated with
PRT1Y (p < 0.0001). Decedents aged 19–44 had 6.7 higher
odds of receiving PRT1Y than those greater than 85 years.
When compared against lung cancer, decedents with
other cancers had significantly smaller odds of receiving
PRT1Y. For instance, colorectal and brain cancer dece-
dents had 0.1 and 0.2 odds of receiving PRT1Y, respect-
ively. When compared with decedents who survived more
than 26 months after their last cancer diagnosis, those
who survived between 1.5 and 26 months had double the
odds of receiving PRT1Y, while decedents who survived
less than 1.5 months after diagnosis had 0.35 odds of re-
ceiving PRT1Y. Decedents who travelled less than 2 hours
to the closest cancer centre had 1.4 odds of receiving
PRT1Y than those who travelled more than 2 hours.
Table 2 Number and percentage of decedents who received PRT1Y
Variable Decedents Number of decedents who received PRT1Y % PRT1Y P value (Chi- square)
Age
<=44 242 78 32.2
45-64 2,327 827 35.5
65-74 2,511 773 30.8
75-84 3,613 724 20.0
85+ 3,607 267 7.4 <.0001
Sex
F 5,734 1,269 22.1
M 6,566 1,400 21.3 0.2774
Primary cancer site
Blood 938 146 15.6
Brain 255 45 17.6
Breast 1,204 236 19.6
Colorectal 1,551 138 8.9
Female genital 623 105 16.9
Lung 2,406 1,099 45.7
Melanoma 265 56 21.1
Non-colorectal GI 1,454 246 16.9
Prostate 1,510 231 15.3
Urinary 1,438 218 15.2
Other 656 149 22.7 <.0001
Survival time from diagnosis (Months)
<1.5 1,812 156 8.6
1.5-26 5,085 1,727 34.0
26+ 5,403 786 14.5 <.0001
Travel time
<=2 hours 9,364 2,120 22.6
>2 hours 2,911 547 18.8 <.0001
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Making sense of PRT utilization
This study showed the overall PRT utilization rate for
EOL cancer decedents in the last year of life was 21.7% in
BC. This rate was similar to those reported by Lavergne
et al. [6] in Nova Scotia (22.5%) for PRT utilization in last
9 months of life and by Huang et al. [4] in Ontario (26.4%)
for last 2 years of life.
When compared with Nova Scotia, our rates were lower
for breast (19.6 vs. 31.5), melanoma (21.1 vs. 39.5) and
prostate (15.2 vs. 27.6) cancer but similar for lung (45.7 vs.
37.3), colorectal (8.9 vs.9.9) and hematologic (15.6 vs.10.3)
cancer. Because different variables were used in the Ontario
study, PRT rates for only three cancer groups could be
compared. Those with breast cancer in Ontario had higher
rates of PRT use, (39.4 vs. 19.6), but similar rates for
hematopoietic (18.6 vs. 15.6) and lung cancers (39.9 vs.
45.7) despite the difference of time frame reported i.e. 2 yearrates in Ontario versus 1 year rates in this study. This study
also found brain cancer decedents had the second highest
RT utilization rate (36.9%) in the last year of life following
after lung cancer; however, only 17.6% of decedents re-
ceived RT deemed palliative by our definition. This is
mainly because brain RT, although palliative by nature, is
not likely to be coded as palliative in this data.
In this study, PRT utilization varied by such factors as
age, diagnosis, survival time and geographic region. Those
younger than 85 years of age, with primary lung cancer,
survival time of 1.5-26 months from diagnosis, or residing
less than 2 hours from a cancer centre had higher rates of
PRT utilization. These results were similar to those identi-
fied by Lavergne et al. [6], except for sex; they found being
female was associated with declined PRT use. Huang et al.
[4] also reported higher likelihood of PRT use among
those with younger age and those living near a cancer
centre.
Table 3 PRT rates in last 30 and 14 days of life by primary cancer diagnosis
Primary cancer diagnosis Study cohort Last 30 days Last 14 days
Decedents % cohort % PRT # course Decedents % cohort % PRT # course
Lung 2,406 272 11.3 24.7 357 129 5.4 11.7 160
Breast 1,204 42 3.5 17.8 54 18 1.5 7.6 20
Colorectal 1,551 30 1.9 21.7 33 16 1.0 11.6 18
Prostate 1,438 43 3.0 19.7 53 20 1.4 9.2 24
Non-colorectal GI 1,454 59 4.1 24.0 69 23 1.6 9.3 24
Blood 938 34 3.6 23.3 50 9 1.0 6.2 17
Urinary 656 36 5.5 24.2 45 11 1.7 7.4 15
Female genital 623 15 2.4 14.3 15 5 0.8 4.8 5
Brain 255 8 3.1 17.8 9 * * 8.9 *
Melanoma 265 13 4.9 23.2 16 * * 7.1 *
Other 1,510 62 4.1 26.8 80 29 1.9 12.6 37
Overall 12,300 614 5.0 23.0 781 268 2.2 10.0 328
% cohort: Proportion of decedents received PRT in their last 30/14 days of life.
% PRT: Proportion of decedents who receive PRT courses in last year of life received PRT in their last 30/14 days of life.
#course: Number of PRT courses that decedents received in their last 30/14 days of life.
*Cell is suppressed due to small count.
Table 4 Odds ratios describing likelihood of receiving
PRT1Y
Variable Adjusted odds ratio 95% CI
Age ( vs. 85+)
<19 5.42 1.59 18.50
19-44 6.68 4.83 9.24
45-64 5.64 4.79 6.64
65-74 4.53 3.86 5.32
75-84 2.62 2.24 3.06
Sex
M (vs. F) 0.97 0.87 1.09
Primary cancer site (vs. Lung)
Blood 0.24 0.19 0.29
Brain 0.16 0.11 0.23
Breast 0.41 0.34 0.50
Colorectal 0.13 0.11 0.16
Female genital 0.25 0.19 0.32
Melanoma 0.43 0.31 0.60
Non-colorectal GI 0.20 0.17 0.24
Prostate 0.38 0.32 0.47
Urinary 0.41 0.33 0.51
Other 0.23 0.19 0.28
Survival time from diagnosis (Months) ( vs. 26+)
<1.5 0.35 0.28 0.42
1.5-26 2.01 1.79 2.25
Travel time
≤2 hours (vs. >2 hours) 1.44 1.28 1.62
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dents was that they had more severe comorbidities,
worse performance status or different treatment prefer-
ences that made PRT less suitable [3,4,6]. The higher
rates for decedents who survived 1.5-26 months may
have been because those who had very short survivals
may have been too sick to benefit from radiotherapy, as
assessed by their oncologists. On the other side of the
spectrum, those with longer survivals may have been
quite well and asymptomatic, not needing cancer treat-
ment, and may have even died of other causes. The vari-
able rates observed across cancer groups are likely due
to difference in symptom frequency/severity or cancer
site-specific indications for radiotherapy or other pallia-
tive treatments.
Regarding regional differences in PRT use, the lowest
PRT rates in this study were in the Northern (i.e. Northeast,
Northern Interior), Vancouver Coastal (i.e. North Shore/
Coast Garibaldi) and Interior regions (i.e. East Kootenay,
Kootenay Boundary, Thompson, Okanagan). One likely rea-
son for the low rates in the Northern region may have been
that there was no cancer centre in the region at the time of
this study, and decedents were generally referred to the
Vancouver centre, which could have been many hours flight
from many parts of the regions. Another was that North
East and East Kootenay HSDAs are close to the neighbour-
ing province of Alberta. It is possible that some decedents
were referred to the radiotherapy centres in Alberta,
which would not be captured in our data [15]. These find-
ings were consistent with other studies that showed the
detrimental effect of increased travel time on reduced
PRT use existed previously, affecting patients as early as
1986 [15,16].
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was the Northwest HSDA in the Northern region which
had the highest rate (28.6) in the province. This could
relate to a high percentage of First Nation population
residing in the region, whose travel may have been more
likely to be paid for. Another was the Interior Okanagan
HSDA that had rates (20.0) below the provincial average
despite having a cancer centre in the region. One reason
could be that 20-40% of the decedents in that HSDA
were more than 2 hours drive away from the cancer
centre. Another reason could be that pre-existing long
wait lists for radiotherapy may have been a significant
disincentive to refer patients for PRT, or patients may
have died or been treated with other palliative measures
prior to PRT becoming available to them.
Because of the methodology of this study, we were un-
able to examine other relevant patient, service and sys-
tem related factors that may influence PRT utilization,
such as functional status and symptoms [13,17], socio-
economic status [4-6,13], hospice care [4], nursing home
residency [6], PRT consultation [5,6], hospital affiliation
[13], wait times [18,19], referral to a formal palliative
care program [20,21], and physicians’ knowledge of PRT
and how active they were involved in palliative care [18].
The availability of formal Palliative Care programs and
hospice care varies greatly among communities in British
Columbia. Further work needs to be done to link the
availability of these services to outcomes.Appropriate PRT use in EOl cancer care
In this study, the proportion of EOL cancer decedents
that received at least one course of PRT in the last 30
and 14 days of life were 5.0% and 2.2%, respectively.
Guadagnolo et al. [13] studied 15,287 SEER-Medicare
decedents (≥65 yrs) who died from malignant diseases of
lung, breast, prostate, colorectal, and pancreas from
2000 to 2007. In that study, 7.6% of the decedents re-
ceived PRT within their last 30 days of life. The lower
rate observed in our study may be partially explained by
the differences in defining the study cohort as well as
the reimbursement systems used in different health care
systems. Despite the underutilization of PRT in end-of-
life care in Guadagnolo et al. study [13] and the others
[2,17,22], due to the relevance of nonclinical factors
found with the use of PRT in the last month of life, we
would argue that the lower rate we found in our study
might indicate the accuracy of physician predictions on
prognosis and thus ‘appropriate’ palliative care, espe-
cially with respect to geographic access. Lower rates are
considered appropriate, as good palliative care for a pa-
tient who lives far away is through use of medication
and avoidance of a long trip that might hasten their
death and negatively impact their overall quality of life.Some studies reported “optimal” PRT utilization rates
based on empirical findings or model estimates. For in-
stance, Huang et al. [4] identified a subgroup of cancer
decedents in Ontario who had more optimal PRT
(2 year) access rate of 57.8%, which was above the aver-
age of 26.4% in their study population. This subgroup
was made up of individuals who were less than 70 years
of age, residents of medium and high income communi-
ties, diagnosed in a hospital with a cancer centre, and
residing near cancer centres with better PRT access.
Based on these findings, Huang et al. concluded that
PRT was underutilized in Ontario. In our study, due to
the lack of neighbourhood income data, we were not
able to construct a comparable cohort to compare the
‘optimal’ PRT rate for BC EOL cancer decedents. It is
impossible to truly asses if PRTs rates found in this study
are “appropriate” or “inappropriate”, given the lack of
individual decedent data about pain and symptom preva-
lence/severity, decedent functional status, and decedent
treatment preferences. Nevertheless, the fact that PRT
rates in our study varied by non-clinical factors such as
age, travel time and geographic region does suggest
underutilization of PRT in a subgroup of population
with suboptimal access.
With the increased emphasis on monitoring EOL care,
further work is needed to assess appropriateness of PRT
rate for EOL cancer decedents in BC, and to develop
benchmark rates that can be practically assessed in dif-
ferent geographic regions. Development of these bench-
mark rates may require richer data collected at the point
of care as well as rigorous/robust methodology based on
a sound scientific footing. Both aspects remain challen-
ging in the current palliative/EOL care research but de-
sire resolution in the future.
Study limitations and implications
This study has three limitations. First, the cause of death
for decedents was not available at the time of data collec-
tion. Therefore the cohort consisted of decedents who died
with rather than of cancer, which could under-estimate
PRT rates. Second, this study used data collected for
administrative purposes. Such clinical factors as symptom
assessment and patient preferences at end of life were not
available, which could provide reasons for PRT use. Third,
PRT practice in BC may not be generalizable outside of
BC, as practice varies by country and training, location and
type of practice, experience and reimbursement.
To the best of our knowledge, this population-based
study is the first of its kind providing data on the use of
PRT for the end of life cancer population in BC. It is
our hope that this information could be used by local
cancer care providers and health care administrators
for cancer care planning as well as researchers conducting
end of life care research. We believe that the findings from
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treatment received by a subgroup of the BC cancer popula-
tion due to restricted geographic access. Identifying the sub-
group who might be receiving suboptimal care at the end of
life will help service planners target this population for qual-
ity improvement. Even though it is not an intention of this
research to identify optimal PRT rates, findings from this
study raises important questions and provides the base PRT
utilization rate at the population level for future research.
Lastly, this study will add province-specific data of BC to
existing data available in other Canadian provinces on the
subject of PRT utilization for palliation. This will increase
the availability of data on provincial comparisons for future
end of life research.
Conclusions
This study examined PRT utilization by cancer decedents
in their last year of life in BC. The overall PRT rate was
21.7%. The likelihood of receiving PRT EOL cancer dece-
dents was higher for those less than 85 years of age, with
primary lung cancer, survival time of 1.5-26 months from
diagnosis, or living less than 2 hours from a cancer centre.
The proportion of EOL cancer decedents who had re-
ceived at least one course of PRT in the last 30 and 14 days
of life were 5.0% and 2.2%, respectively. It is not clear
whether these rates are considered optimal as there are no
established PRT utilization rates for EOL cancer dece-
dents at present.
Additional files
Additional file 1: Appendix A. Distribution of Doses for RT courses
with “Palliative Intent” Code. Among all the RT courses (4776) prescribed
to the study cohort during the last year of life, 88.4% (4221) of the
courses had a “palliative intent” code. The majority (94.5%) of them were
prescribed with dose < =30 Gy.
Additional file 2: Appendix B. Definitions of Primary Cancer Diagnosis.
This file provides the details about the cancer diagnosis (ICD-O-3) codes
used in this study.
Abbreviations
PRT: Palliative radiotherapy; RT: Radiotherapy; EOL: End of life; BCCA: BC
cancer agency; HSDA: Health service delivery area; CAIS: Cancer agency
information system; OR: Odds ratio; CI: Confidence interval.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JH: conceived of the study; led the study design and performed the
statistical analysis; helped to draft and revise the manuscript; EW: contributed
to revising the draft manuscript critically for important intellectual content;
FL: drafted the manuscript and contributed to acquisition of data; PB:
contributed to the revision of manuscript. All of the authors contributed to
the interpretation of the data and approved the final version submitted for
publication.
Acknowledgements
The authors thank Jeff Barnett for his assistance on obtaining access to data
from the BC Cancer Agency for this project.Author details
1School of Health Information Science, University of Victoria, PO BOX 1700
STN CSC, Victoria, British Columbia, Canada. 2Department of Surgery, Faculty
of Medicine, University of British Columbia, 950 West 10th. Avenue,
Vancouver, BC, Canada. 3Division of Radiation Oncology, BC Cancer Agency,
Vancouver Island Centre, 2nd Floor, 2410 Lee Avenue, Victoria, BC, Canada.
Received: 30 June 2014 Accepted: 29 October 2014
Published: 18 November 2014
References
1. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A,
Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A,
Bruner DW, Hartsell W: Palliative radiotherapy for bone metastases: an
ASTRO evidence-based guideline. Int J Radiation Oncol Biol Phys 2011,
79(4):965–976.
2. Fine P: Palliative radiation therapy in end-of-life care: evidence-based
utilization. Am J Hosp Palliative Med 2002, 19:166–170.
3. Hayman JA, Abrahamse PH, Lakhani I, Earle CC, Katz SJ: Use of palliative
radiotherapy among patients with metastatic non-small-cell lung cancer.
Int J Radiation Oncology Biol Phys 2007, 69(4):1001–1007.
4. Huang J, Zhou S, Groome P, Tyldesley S, Zhang-Solomans J, Mackillop WJ:
Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol
2001, 19:137–144.
5. Johnston GM, Boyd CJ, Joseph P, Maclntyre M: Variation in delivery of
palliative radiotherapy to persons dying of cancer in Nova Scotia, 1994
to 1998. J Clin Oncol 2001, 19:3323–3332.
6. Lavergne MR, Johnston GM, Gao J, Dummer TJB, Rheaume DE: Variation in
the use of palliative radiotherapy at the end of life: examining
demographic, clinical, health service, and geographic factors in a
population-based study. Pall Med 2010, 25(2):101–110.
7. BC Annual population 1867–2012. 2012. Available at http://www.bcstats.gov.
bc.ca/StatisticsBySubject/Demography/PopulationEstimates.aspx. Accessed
December 12.
8. BCCA website. [http://www.bccancer.bc.ca/HPI/CancerStatistics/default.htm]
9. Henkelman D: The evolution of a health information brokering service in
the province of British Columbia. Electron Healthc 2003, 2(2):16–21.
10. Tyldesley S, Boyd C, Schulze K, Math M, Walker H, Mackillop WJ: Estimating
the need for radiotherapy for lung cancer: an evidence-based,
epidemiologic approach. Int J Radiat Oncol Biol Phys 2001, 49(4):973–985.
11. Lau F, Downing M, Tayler C, Fassbender K, Lesperance M, Barnett J: Toward
a population based approach in end of life care surveillance in Canada:
Initial efforts and lessons. J Pall Care 2013, 29(1):13–21.
12. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC: Trends
in the aggressiveness of cancer care near the end of life. J Clin Oncol
2004, 22(2):315–321.
13. Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA: Use of radiation
therapy in the last 30 days of life among a large population-based cohort
of elderly patients in the United States. J Clin Oncol 2013, 31(1):80–87.
14. Tyldesley S, McGahan C: Utilisation of radiotherapy in rural and urban
areas in British Columbia compared with evidence-based estimates of
radiotherapy needs for patients with breast, prostate and lung cancer.
Clin Oncol 2010, 22:526–532.
15. Soo J, French J, McGahan CE, Duncan G, Lengoc S: A retrospective study
on accessibility of palliative radiation therapy in the management of
prostate cancer in British Columbia. J Rad in Prac 2011, 10:159–172.
16. French J, McGahan C, Duncan G, Mmath CC, Soo J, Lengoc S: Inequities in
access: how utilization of palliative radiation therapy in British Columbia
varies with geography. J Med Imaging Radiat Sci 2008, 39:75–80.
17. Dennis K, Wong K, Zhang L, Culleton S, Nguyen J, Holden L, Jon F, Tsaon M,
Danjoux C, Bames E, Sahgal A, Zeng L, Koo K, Chow E: Palliative
radiotherapy for bone metastases in the last 3 months of life:
Worthwhile or futile? Clin Oncol 2011, 23:709–715.
18. Gillan C, Briggs K, Pazos AG, Maurus M, Harnett N, Catton P, Wiljer D:
Barriers to accessing radiation therapy in Canada: a systematic review.
Radiat Oncol 2012, 7:167.
19. Fairchild A, Ghosh S, Baker J: Patterns of referral and knowledge of
palliative radiotherapy in Alberta. Can Fam Physician 2012, 58:e113–e122.
20. Johnston GM, Gibbons L, Burge FI, Dewar RA, Cummings I, Levy IG:
Identifying potential need for cancer palliation in Nova Scotia.
CMAJ 1998, 158:1691–1698.
Huang et al. BMC Palliative Care 2014, 13:49 Page 10 of 10
http://www.biomedcentral.com/1472-684X/13/4921. Burge FI, Lawson BJ, Johnston GM, Grunfeld E: A population-based study
of age inequalities in access to palliative care among cancer patients.
Med Care 2008, 46(12):1203–1211.
22. Turner NJ, Muers MF, Haward RA, Mulley GP: Do elderly people with lung
cancer benefit from palliative radiotherapy? Lung Cancer 2005, 49:193–202.
doi:10.1186/1472-684X-13-49
Cite this article as: Huang et al.: Palliative radiotherapy utilization for
cancer patients at end of life in British Columbia: retrospective cohort
study. BMC Palliative Care 2014 13:49.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
